Results 41 to 50 of about 424,341 (313)

Stimulation of mTORC2 by integrin αIIbβ3 is required for PI3Kβ-dependent activation of Akt but is dispensable for platelet spreading on fibrinogen

Platelets, 2020
Phosphatidylinositol 3 kinase (PI3K) is a major player in platelet activation and regulates thrombus formation and stabilization. The β isoform of PI3K is implicated in integrin αIIbβ3 outside-in signaling, is required for the phosphorylation of Akt, and
Mauro Torti, Daria Manganaro, Caterina Visconte, Marta Zarà, Jessica Canino, Mauro Vismara, Ilaria Canobbio, Gianni Francesco Guidetti   +7 more
doaj   +1 more source

Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer’s Disease

Molecules, 2020
Alzheimer’s disease (AD) is one of the utmost chronic neurodegenerative disorders, which is characterized from a neuropathological point of view by the aggregates of amyloid beta (Aβ) peptides that are deposited as senile plaques and tau ...
Md. Sahab Uddin, Md. Tanvir Kabir, Kamal Niaz, Philippe Jeandet, Christophe Clément, Bijo Mathew, Abdur Rauf, Kannan R.R. Rengasamy, Eduardo Sobarzo-Sánchez, Ghulam Md Ashraf, Lotfi Aleya   +10 more
doaj   +1 more source

The Activation of PI3K/AKT/mTOR Signaling Pathway in Response to Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer Cells

European Journal of Biology, 2021
Objective: Despite advances in treatment approaches, metastatic castration-resistant prostate cancer (mCRPC) remains a clinical challenge to treat. Cabazitaxel (Cab), a third-line chemotherapy option for mCRPC, exhibits limited efficiency due to the ...
Işıl Ezgi Eryılmaz, Gamze Güney Eskiler, Ceyda Çolakoğlu, Ünal Egeli, Gülşah Çeçener   +4 more
doaj   +1 more source

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. [PDF]

, 2016
mTOR inhibition has emerged as a promising strategy for head and neck squamous cell carcinomas (HNSCC) treatment. However, most targeted therapies ultimately develop resistance due to the activation of adaptive survival signaling mechanisms limiting the ...
Amornphimoltham, Panomwat, Califano, Joseph A, Callejas-Valera, Juan Luis, Cohen, Ezra E, Gutkind, J Silvio, Iglesias-Bartolomé, Ramiro, Lippman, Scott M, Luo, Ji, Molinolo, Alfredo A, Wang, Zhiyong, Yamaguchi, Kosuke   +10 more
core   +1 more source

mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node

Orphanet Journal of Rare Diseases
Mechanistic target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that regulates key cellular processes including cell growth, autophagy and metabolism.
Laura Mantoan Ritter, Nicholas M. P. Annear, Emma L. Baple, Leila Y. Ben-Chaabane, Istvan Bodi, Lauren Brosson, Jill E. Cadwgan, Bryn Coslett, Andrew H. Crosby, D. Mark Davies, Nicola Daykin, Stefanie Dedeurwaerdere, Christina Dühring Fenger, Elaine A. Dunlop, Frances V. Elmslie, Marie Girodengo, Sophie Hambleton, Anna C. Jansen, Simon R. Johnson, Kelly C. Kearley, John C. Kingswood, Liisi Laaniste, Katherine Lachlan, Andrew Latchford, Ralitsa R. Madsen, Sahar Mansour, Simeon R. Mihaylov, Louwai Muhammed, Claire Oliver, Tom Pepper, Lettie E. Rawlins, Ina Schim van der Loeff, Ata Siddiqui, Pooja Takhar, Katrina Tatton-Brown, Andrew R. Tee, Priyanka Tibarewal, Charlotte Tye, Sila K. Ultanir, Bart Vanhaesebroeck, Benjamin Zare, Deb K. Pal, Joseph M. Bateman   +42 more
doaj   +1 more source

Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

OncoImmunology, 2018
mTOR inhibition can promote or inhibit immune responses in a context dependent manner, but whether this will represent a net benefit or be contraindicated in the context of immunooncology therapies is less understood.
Sophie Langdon, Adina Hughes, Molly A. Taylor, Elizabeth A. Kuczynski, Deanna A. Mele, Oona Delpuech, Laura Jarvis, Anna Staniszewska, Sabina Cosulich, Larissa S. Carnevalli, Charles Sinclair   +10 more
doaj   +1 more source

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system

OncoImmunology, 2020
Effective treatment of invasive lobular carcinoma (ILC) of the breast is hampered by late detection, invasive growth, distant metastasis, and poor response to chemotherapy.
Sjoerd Klarenbeek, Chris W. Doornebal, Sjors M. Kas, Nicola Bonzanni, Jinhyuk Bhin, Tanya M. Braumuller, Ingrid van der Heijden, Mark Opdam, Philip C. Schouten, Kelly Kersten, Roebi de Bruijn, Daniel Zingg, Julia Yemelyanenko, Lodewyk F.A. Wessels, Karin E. de Visser, Jos Jonkers   +15 more
doaj   +1 more source

Mechanistic target of rapamycin (mTOR) signaling genes in decapod crustaceans: cloning and tissue expression of mTOR, Akt, Rheb, and S6 kinase in the green crab, Carcinus maenas, and blackback land crab, Gecarcinus lateralis [PDF]

, 2014
Mechanistic target of rapamycin (mTOR) controls global translation of mRNA into protein by phosphorylating p70 S6 kinase (S6K) and eIF4E-binding protein-1. Akt and Rheb, a GTP-binding protein, regulate mTOR protein kinase activity. Molting in crustaceans
Abuhagr, Ali M., Chang, Ernest S., MacLea, Kyle S., Mykles, Donald L.   +3 more
core   +2 more sources

The role of fibroblast growth factors in cell and cancer metabolism

FEBS Letters, EarlyView.
Fibroblast growth factor (FGF) signaling regulates crucial signaling cascades that promote cell proliferation, survival, and metabolism. Therefore, FGFs and their receptors are often dysregulated in human diseases, including cancer, to sustain proliferation and rewire metabolism.
Jessica Price, Chiara Francavilla
wiley   +1 more source

Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice [PDF]

, 2014
Kristyn A Liu1†, Laura M Lashinger1†, Audrey J Rasmussen1† and Stephen D Hursting12* Author Affiliations 1 Department of Nutritional Sciences, University of Texas at Austin, Austin, TX 78723, USA 2 Department of Molecular Carcinogenesis, University ...
Hursting, Stephend D., Lashinger, Laura M., Liu, Kristyn A., Rasmussen, Audrey J.   +3 more
core   +1 more source